The National Agency for Food and Drug Administration and Control (NAFDAC) says it will continue hydroxychloroquine clinical trials for COVID-19 treatm
The National Agency for Food and Drug Administration and Control (NAFDAC) says it will continue hydroxychloroquine clinical trials for COVID-19 treatment despite the suspension of the drug test by the World Health Organisation (WHO).
On Monday, WHO had announced a temporary pause in its solidarity trial on the use of hydroxychloroquine for treatment of COVID-19 patients. Tedros Ghebreyesus, the WHO director-general, cited a study published which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
But the NAFDAC DG, Mojisola Adeyeye, said there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the “mild stage” of the virus. She said Nigeria would continue its clinical trials which may take three to four months.
“There is data to prove that hydroxychloroquine worked for many COVID-19 patients. Therefore, we would continue our own clinical trials in Nigeria. Hydroxychloroquine has been proved to work at a mild stage.
“So the potency depends on the severity of the disease in the patient’s body. If medical doctors, research scientists, pharmacists, herbal experts work together, we should conclude the clinical trial in three to four months. The narrative might change afterwards but for now, we believe in hydroxychloroquine,” she said.
